Methods for diagnosing and monitoring eosinophilic esophagitis

ABSTRACT

Disclosed are compositions and methods for diagnosing eosinophilic esophagitis in a subject. Also disclosed are methods for monitoring the course of eosinophilic esophagitis in a subject before, during, and after treatment. In another aspect, disclosed is a method of diagnosing eosinophilic esophagitis or eosinophilic diseases in a subject, comprising detecting an eosinophil granule protein in the mucosal tissue of the esophagitis or other organs in a subject.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional PatentApplication No. 61/688,650, filed on May 18, 2012, and U.S. ProvisionalPatent Application No. 61/786,909, filed on Mar. 15, 2013. U.S.Provisional Patent Application No. 61/688,650 and U.S. ProvisionalPatent Application No. 61/786,909 are hereby incorporated herein byreference in their entireties.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH

This invention was made with government support under NSF CBET(CBET-1125490) and NIH ROI A109728. The government has certain rights inthis invention.

FIELD OF THE INVENTION

This invention related generally to the field of diagnostics. Thus,disclosed are compositions and methods for diagnosing and monitoringeosinophil degranulation-associated esophagitis in a subject, using aradiolabeled contrast agent administered orally to a subject.Specifically, disclosed are compositions and methods for diagnosing andmonitoring eosinophilic esophagitis in a subject, using radiolabeledheparin.

BACKGROUND

Eosinophilic esophagitis (EoE) is a chronic disease of the esophagusthat affects over 300,000 patient in the U.S. alone. Symptoms includedysphagia (difficulty swallowing liquids or solids or both, >90%), foodimpaction (sold food sticks in the esophagus, 50%), odynophagia (painfulswallowing), heartburn (33%), chest pain, asthma (50%), diarrhea, andvomiting (Gonzales, Karallas, Am J Gastroenterology, 2009). The diseaseprimarily occurs in males (75%) with a mean age between 36 and 42 yearsin westernized countries. While present in adults, the disease can alsomanifest in children. The symptoms of EoE are similar to an atopicallergenic inflammatory condition of the esophagus, affecting up to 10%of adults presenting for upper endoscopy (Mackenzie, Aliment TherPharmacol, Gastroenterol, 2008).

Although the source or sources of this disease have not beenconclusively identified, investigators have identified severalcontributing factors. Genetic predisposition may be at work in thisdisease, at least in part, due to the increased incidence in firstdegree relative of EoE patients relative to the general population.Environmental causes may also be important as allergens (i.e., food andaero-allergens) contribute in up to 97% of cases in children (Liacouras,Clin Gastro Hep, 2005). Fogg et al. (2007) subsequently identified aseasonal variation in identification and severity of the disease inchildren. Furthermore, Mishra et al. (2001) determined that intranasaladministration of Aspergillus fumigatus in a mouse model replicated theesophageal eosinophilic infiltrate seen in EoE. However, EoE is notsimply a seasonal allergy of the esophagus. Despite current treatmentwith swallowed aerosolized steroids, the response rate is little betterthan 50% (Konikoff, Gastroenterology, 2007).

Food allergies also play an important role in both adult and pediatricEoE. Markowitz et al. (2003) found resolution of esophageal eosinophiliaafter 4 weeks of amino acid-based elemental diet in 49/51 pediatricpatients. In the largest analysis to date, Liacouras et al. (2005) founda 97% response to an elemental diet in a cohort of 160 children withEoE. However, preliminary data on an elimination diet in adults foundless robust responses than those observed in children. This six-foodelimination diet (Gonsalves et al., 2012) demonstrated improvement in78% and 33% complete resolution rate. Elemental diet in adults resultsin substantial improvement in eosinophilia after 4 weeks in 72% ofpatients (Peterson, 2013). Responses to skin prick testing in adultsundergoing food elimination diets suggest a multi-model (IgE and non-IgEmediated) immunological process, and murine models find bothaero-allergens food each play significant roles (Mishra, J Clin Invest,2001).

In all cases, detection of EoE via a form of endoscopy known asesophagoduodenoscopy (EGD) remains essential. in this procedure, a smalltube with a camera on the distal end is passed into the esophagus,stomach, and first portion of the small intestine to visualize themucosal surfaces of these organs. In EoE, the inflammation occurs invarious parts of the esophagus; there is approximately equal incidencein the proximal, distal or both portions of the esophagus being affected(Gangotena, Am J Gastroenterol, 2007) within cohorts, but suchinfiltrate varies in each individual with many demonstrating a lessintense infiltrate proximally. EoE also affects the luminal structure ofthe esophagus. Pronounced rings or furrows can develop into stricturesthat close off the esophagus, resulting in odynophagia, dysphagia, foodimpaction, and emergency hospital visits. The areas of inflammation arenot evenly distributed throughout an affected esophagus, as the diseaseoften presents in patches or select segments of the 25-30 cm long adultesophagus.

Although EGD is a key tool in the identification of EoE, some cases maynever present as a “ringed-esophagus” during EGD. A conclusive meanscurrently available to clinicians to positively identify EoE is todetect the presence of eosinophils in biopsy specimens. Tissue samplesmay be collected during EGD and then examined with traditionalhistological analysis to confirm or reject a cade of EoE. However, thepatchy nature of the disease complicates collection of tissue samplesfor biopsy. When clinical suspicion for EoE is high, consensus practicerequires sampling at 4 to 5 sites throughout the esophagus. However,five 2 mm biopsy specimens represent less than 0.7% of the 29- to25-cm-long esophageal mucosa and might result in underdiagnosis of EoEif mucosal eosinophilia is particularly patchy. Specific diseasephenotypes (i.e., rings, lines, furrows, white spots, or plaques) aidphysicians in determining where and how many biopsies to perform basedon EGD-observed phenotypes, which are strong indicators of eosinophildensity. For example, biopsies to collect tissue samples are oftencollected from unaffected areas. For this reason, at least 4 (child) or6 (adult) biopsy specimens are required to confirm each case of EoE(Gonsalves Gastrointestinal Endosc, 2006; Shah Am J Gastroenterol,2009). Furthermore, additional biopsies are required to evaluate theeffectiveness of each treatment proposed. This repeated need forendoscopic removal of tissue poses a financial hardship for the patient,and the procedure can be painful, requiring sedation and/or anesthesia.

The key element for diagnosing EoE in a biopsy specimen is the presenceof eosinophils. Normal esophageal tissue does not contain eosinophils(Kato et al., 1998) These white blood cells were named for theiraffinity for the red dye eosin. Normally, eosinophils reside in theblood stream, stomach, small and large intestine, and lymphatic system(Kato et al., 1998) but infiltrate pathologically into the esophagus inEoE. In biopsy samples, an eosinophil can be identified as a cell 12-17μm in diameter with a bi-lobed nucleus and cytoplasmic granules stainingred with acidic dyes, for example eosin. A tissue count of eosinophilsin excess of 15 per field of view at high microscope power (greater than15 per high-powered field (hpf)) indicates EoE. Some clinical evidencesuggests that inflammation increases with eosinophil concentration.

A distinctive characteristic of eosinophils is their granules whichcomprise markedly cationic proteins, each of which is composed of a coreand a matrix. The core consists primarily of major basic protein 1(MBP-1); the matrix consists of eosinophil peroxidase (EPO) andeosinophil derived neurotoxin (EDN) (Peters et al., 1986), inter alia.MBP-1 is a highly basic (isoelectric point approaching 12) 13.8 kDaprotein with 5 unpaired cysteins that accounts for about 55% of thegranule's protein (Gleich et al., 1974; Gleich et al., 1976). It is amember of the C-type lectin family (lectins bind sugars) and has thehighest concentration in the eosinophil granule on a per molecule basis(Abu-Ghazaleh et al., 1992). EPO has the highest concentration in thegranule on a per mass basis, while EDN and CEP are members of the RNAse2 family (Gleich et al., 1986). Upon degranulation, an eosinophilreleases each of these proteins into the surrounding tissues. Of these,only MBP-1 stimulates histamine release (O'Donnell et al., 1983). MBP-1also exfoliates bronchial epithelial cells (Frigas et al., 1980) andcauses bronchial hyper-reactivity (Gundel et al., 1991), whereas bothMBP-1 and EPO provoke transient bronchial constriction (Gundel et al.,1991). These proteins are found in abundance in biopsies in eosinophilicesophagitis (Kephart, Am J Gastroenterol, 2010).

Currently, as symptoms are unable to predict the severity ofeosinophilic involvement, the only way to adequately monitor the extentand severity of the disease is through invasive upper endoscopy withbiopsy. Often, in food re-introduction and therapeutic evaluation, thisresults in several upper endoscopies per year for patients. Due to thecost, invasiveness, and discomfort experienced via this method ofmonitoring, patients become non-compliant, and subsequently the diseaseis not adequately tracked. Additionally, there is a lack of sensitivityof biopsies in detecting and understanding such a patchy disease becausebiopsies histologically characterize only <0.03% of the entireesophagus.

Despite the rapidly growing incidence of EoE, state-of-the-artdiagnostic techniques remain inadequate to fully characterize thisdisease. As such, there exists a need to develop a non-invasive,precise, and comprehensive technique to image and map the distributionof inflammation and deposition of eosinophil granule proteins. Suchtechniques will provide a tool to diagnose EoE, track disease activityin response to various treatment regimens, and obtain previouslyunreachable insight into the development and progression of EoEpathophysiology.

SUMMARY

In accordance with the purposes of this invention, as embodied andbroadly described herein, disclosed, in one aspect, is a method ofproducing a medical image of an esophagus in a subject, comprisingdetecting an eosinophil granule protein in the mucosal tissue of theesophagus in a subject, comprising administering to a subjectradiolabeled heparin, under conditions wherein the radiolabeled heparincan bind to an eosinophil granule protein, and detecting a radiolabeledheparin/eosinophil granule protein complex in the mucosal tissue of theesophagus, whereby detecting the radiolabeled heparin/eosinophil granuleprotein complex in the mucosal tissue of the esophagus produces amedical image of the esophagus in the subject.

In another aspect, disclosed is a method of diagnosing eosinophilicesophagitis or eosinophilic diseases in a subject, comprising detectingan eosinophil granule protein in the mucosal tissue of the esophagus orother organs in a subject, comprising administering to a subjectradiolabeled heparin under conditions wherein the radiolabeled heparincan bind to an eosinophil granule protein, and detecting a radiolabeledheparin/eosinophil granule protein complex in the mucosal tissue of theesophagus or other organs, whereby detecting the radiolabeledheparin/eosinophil granule protein complex in the mucosal tissue of theesophagus diagnoses eosinophilic esophagitis or eosinophilic diseases inthe subject.

In another aspect, disclosed is a method of detecting a change ineosinophilic esophagitis in a subject diagnosed with eosinophilicesophagitis, comprising: a) producing a first medical image of theesophagus in a subject diagnosed with eosinophilic esophagitis accordingto the disclosed methods, b) producing a second medical image of theesophagus in the subject of step (a) according to the disclosed methods,and c) comparing the medical image of step (b) with the medical image ofstep (a), whereby detecting a change in the medical image of step (b)compared to the medical image of step (a) detects a change ineosinophilic esophagitis in the subject.

In another aspect, disclosed is a method of detecting eosinophildegranulation in a subject, comprising detecting an eosinophil granuleprotein in a subject, comprising administering to a subject radiolabeledheparin under conditions wherein the radiolabeled heparin can bind to aneosinophil granule protein, and detecting a radiolabeledheparin/eosinophil granule protein complex, whereby detecting theradiolabeled heparin/eosinophil granule protein complex detects thepresence of eosinophil degranulation in the subject.

BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying figures, which are incorporated in and constitute apart of this specification, illustrate several aspects and together withthe description serve to explain the principles of the invention.

FIG. 1 shows a 2D planar SPECT image of biopsies from active EoE (>15eosinophil (eos) per high power field (hpf) of view) and resolved EoEpatients (<15 eos/hpf) after being incubated with ^(99m)Tc-heparin.

FIG. 2 shows SPECT count of biopsies a function of eosinophil countsfrom the same patients as shown in FIG. 1.

FIG. 3 shows ^(99m)Tc-heparin binding affinity. Samples were preparedusing 100 mCi of ^(99m)Tc fresh tin solution heparin (150 mg). Sampleswere run through a Hi-trap G25 desalting column, and paperconfirmed >97% binding. (A) Shows the radiolabel activity of eachcollected chromatography fraction, which consisted of 30 drops andconstituted roughly 1 mL. (B) Shows absorbance of each fraction oat 230nm. There were no second peaks of unbound ^(99m)Tc, and the activitypeak correlates with the absorbance peak.

FIG. 4 shows ^(99m)Tc-heparin binding to monkey esophagus biopsy tissue.(A) Shows a high level of initial activity or samples treated with MBP-1compared to control. The level of activity decreases with subsequentwashes before leveling out above control after the fourth wash. (B) Showthe effect of time on activity in samples treated with MBP-1. (C) Showsthat activity within a sample reaches a saturation point between 1 and 2mM treatment with ^(99m)Tc-heparin.

FIG. 5 shows a SPECT intensity image of a sample of monkey esophagealtissue. The monkey esophagus was incubated overnight with PBS (control)or MBP-1 (treated). Following this initial control versus treatedincubation, the samples were incubated with ^(99m)Tc-heparin. Therepresentative result clearly demonstrates that ^(99m)Tc-heparinintensity is significantly higher in the MBP-1 treated monkey esophagealtissue.

FIG. 6 shows ex vivo biodistribution of orally administered^(99m)Tc-heparin as measured using a well counter at different timepoints. Mean and standard deviation of % ID/g were corrected forphysical decay of the isotope.

FIG. 7 shows SPECT/CT images of orally administered ^(99m)Tc-heparininto mice at 3, 6, 18, and 30 hours. St=stomach; In=Intestines.

FIG. 8 shows average net activity (μCi) of radiolabeling in differentorgans at each time interval that mice were sacrificed. The differentorgans tested include (A) esophagus, (B) stomach, (C) proximal largeintestine, (D) distal large intestine, and (E) small intestine. Theaverage is represented by the bullet, and the 95% confidence interval isrepresented by the error bars. Because only one data point was availablefor some time intervals, no error bars are shown.

FIG. 9 shows intravenous-based localization of eosinophil granuleproteins. Mice were injected subcutaneously with granule proteins MBP-1and EPO at six sites (A), followed by tail vein administration of^(99m)Tc-heparin, the same conjugate used for oral administration. After60 minutes (B), and 105 minutes (C-E), activity was apparent at thesubcutaneous MBP-1/EPO injection sites (arrows) The location of MBP-1and EPO can be identified at relevant concentrations, with higherconcentration injections accumulating more of the ^(99m)Tc-heparin.

DETAILED DESCRIPTION

What is needed in the art are compositions and non-invasive methods fordiagnosing eosinophil degranulation-associated esophagitis in a subjectand for monitoring the effectiveness of treatment in the subject inorder to decrease suffering and cost and to increase subject compliance.Eosinophil degranulation-associated esophagitis is eosinophilicesophagitis (EoE). The disclosed methods can diagnose eosinophilicesophagitis in a subject by detecting the presence of eosinophil granuleproteins in the esophageal mucosal tissue. Thus, the diagnosis can bemade even when morphologically intact eosinophils cannot be found in theinflamed tissue under microscopic examination.

Thus, disclosed is the surprising discovery that anionic heparinradiolabeled with Technetium-99m (i.e., ^(99m)Tc or Tc-99m) can be useda contrast agent probe to localize cationic eosinophil granule proteins,which are absent in the normal esophagus but are deposited in and areassociated with inflammation in the mucosal tissue of the esophagusafter eosinophil degranulation in a subject with EoE.

The present invention may be understood more readily by reference to thefollowing detailed description of various aspects of the invention andthe Examples included therein and to the Figures and their previous andfollowing description.

Before the present compounds, compositions, articles, devices, and/ormethods are disclosed and described, it is to be understood that thisinvention is not limited to specific synthetic methods or specificradiolabeled contrast agents, as such may, of course, vary. It is alsoto be understood that the terminology used herein is for the purpose ofdescribing particular aspects only and is not intended to be limiting.

As used in the specification and the appended claims, the singular forms“a,” “an,” and “the” include plural referents unless the context clearlydictates otherwise. Thus, for example, reference to “a radiolabeledcontrast agent” or a “radiolabeled heparin/eosinophil granule proteincomplex” can include mixtures of radiolabeled contrast agents ormixtures of radiolabeled heparin/eosinophil granule protein complexes,respectively, and the like.

Ranges may be expressed herein as from “about” one particular valueand/or to “about” another particular value. When such a range isexpressed, another aspect includes from the one particular value and/orto the other particular value. Similarly, when values are expressed asapproximations, by use of the antecedent “about,” it will be understoodthat the particular value forms another aspect. It will be furtherunderstood that the endpoints of each of the ranges are significant,both in relation to the other endpoint and independently of the otherendpoint.

Disclosed are materials, compositions, and components that can be usedfor, can be used in conjunction with, can be used in preparation for, orare products of the disclosed methods and compositions. These and othermaterials are disclosed herein, and it is understood that whencombinations, subsets, interactions, groups, etc. of these materials aredisclosed that while specific reference of each various individual andcollective combinations and permutations of these compounds may not beexplicitly disclosed, each is specifically contemplated and describedherein. For example, if a radiolabeled contrast agent is disclosed anddiscussed an a number of modifications that can be made to a number ofmolecules including the radiolabel and contrast agent are discussed,each and every combination and permutations of the radiolabel andcontrast agent and the modifications that are possible are specificallycontemplated unless specifically indicated to the contrary. Thus, if aclass of molecules, A, B, and C is disclosed as well as a class ofmolecules D, E, and F and an example of a combination molecule A-d isdisclosed, then even if each is not individually recited, each isindividually and collectively contemplated Thus, in this example, eachof the combinations A-E, A-F, B-D, B-E, B-F, C-D, C-E, and C-F isspecifically contemplated and should be considered disclosed fromdisclosure of A, B, and C; D, E, and F; and the example combination A-D.Likewise, any subset or combination of these is also specificallycontemplated and disclosed. Thus, for example, the sub-groups of A-E,B-F, and C-E are specifically contemplated and should be considereddisclosed from disclosure of A, B, and C; D, E, and F; and the examplecombination A-D. This concept applies to all aspects of this applicationincluding, but not limited to, steps in the methods of making and usingthe disclosed radiolabeled contract agents and radiolabeledheparin/eosinophil granule protein complexes. Thus, if there are avariety of additional steps that can be performed, it is understood thateach of these additional steps can be performed with any specific aspector combination or aspects of the disclosed methods and that each suchcombination is specifically contemplated and should be considereddisclosed.

Those skilled in the art will recognize, or be able to ascertain usingno more than routine experimentation, many equivalents to the specificaspects of the methods and compositions described herein. Suchequivalents are intended to be encompassed by the appended claims.

Unless defined otherwise, all technical and scientific terms used hereinhave the same meanings as commonly understood by one of skill in the artto which the disclosed methods and compositions belong. Although anymethods and materials similar or equivalent to those described hereincan he used in the practice or testing of the disclosed methods andcompositions, the particularly useful methods, devises, and materialsare as described.

Throughout this application, various publications are referenced. Thedisclosures of these publications in their entireties are herebyincorporated by reference into this application in order to more fullydescribe the state of the art to which this pertains. The referencesdisclosed are also individually and specifically incorporated byreference herein for the material contained in them that is discussed inthe sentence in which the reference is relied upon. Nothing herein is tobe construed as an admission that the present invention is not entitledto antedate such disclosure by virtue of prior invention. No admissionis made that any reference constitutes prior art. The discussion ofreferences states what their authors assert, and applicants reserve theright to challenge the accuracy and pertinence of the cited documents.

It is understood that the disclosed methods and compositions are notlimited to the particular methodology, protocols, and reagentsdescribed, as these may vary. It is also to be understood that theterminology used herein is for the purpose of describing particularaspects only and is not intended to limit the scope of the presentinvention which will be limited only by the appended claims.

in this specification and in the claims which follow, reference will bemade to a number of terms which shall be defined to have the followingmeanings. The word “comprise” and variations of the word, such as“comprising” and “comprises,” means “including, but not limited to” andis not intended to exclude, for example, other additives, components,integers or steps. “Optional” or “optionally” means that thesubsequently described event or circumstance may or may not occur andthat the description includes instances where said event or circumstanceoccurs and instances where it does not. As used herein, by “subject” ismeant an individual. A subject can be a mammal such as a primate, forexample, a human. The term “subject” includes domesticated animals suchas cats, dogs, etc., livestock (e.g., cattle, horses, pigs, sheep,goats, etc.), and laboratory animals (e.g., mice, rabbits, rats,gerbils, guinea pigs, possums, etc.), As used herein, the terms“subject” and “patient” are interchangeable.

Disclosed are compositions and non-invasive methods for diagnosing EoEin a subject and for monitoring the course of the disease before,during, and after treatment of the disease. Thus, provided is a methodof producing a medical image of an esophagus in a subjects, comprisingdetecting an eosinophil granule protein in the mucosal tissue of theesophagus in a subject, comprising administering to a subjectradiolabeled heparin under conditions wherein the radiolabeled heparincan bind to an eosinophil granule protein, and detecting a radiolabeledheparin/eosinophil granule protein complex in the mucosal tissue of theesophagus, whereby detecting the radiolabeled heparin/esoinophil granuleprotein complex in the mucosal tissue of the esophagus produces amedical image of the esophagus in the subject. In one aspect, themedical image can be three-dimensional. In another aspect, the medicalimage can be two-dimensional.

As used herein, a “mucosal tissue” is a tissue lining carious cavitieswithin the body Examples of a mucosal tissue include, but are notlimited to, mucosal tissue lining the nose, sinuses, bronchi, lungs,conjunctiva, oral cavity, tongue, esophagus, stomach, pylorus, duodenum,jejunum, ileum, ascending colon, caccum, appendix, transverse colon,descending colon, rectum, anus, urethra, and urinary bladder. A mucosaltissue comprises an epithelial surface, glandular epithelium whichsecretes mucus, basement membrane, and submucosa with connective tissue.thus, a radiolabeled heparin/eosinophil granule protein complex can bedetected on the epithelial surface, in the glandular epithelial tissue,on or in the basement membrane, and in the submucosal connective tissueof a mucosal tissue in a subject. In one aspect, a mucosal tissue isfrom the esophagus of a subject.

As used herein, and “eosinophil granule protein” is a protein thatcomprises the granules in eosinophils. When an eosinophil is activated,granule proteins are released from the cell into the surrounding tissue.The released granule proteins can cause pathologic allergenicinflammatory responses in the surrounding tissue, for example,esophageal mucosal tissue. Examples of eosinophil granule proteinsinclude, but are not limited to, major basic protein (MBP), major basicprotein 1 (MBP-1), major basic protein 2 (MBP-2), eosinophil derivedneurotoxin (EDN), eosinophil cationic protein (ECP), and eosinophilperoxidase

Other examples of eosinophil granule proteins are provided in Kita etal., Biology of Eosinophils, Chapter 19 of Immunology, which is herebyincorporated by reference for its teaching of examples of eosinophilgranule proteins. In one aspect, an eosinophil granule protein can beMBP-1.

As used herein, a “radiolabel” is an isotopic composition that can beattached to a substance, for example heparin, to track the substance asit passes through a system or tissue. A non-limiting example of aradiolabeled substance is radiolabeled heparin. In one aspect, aradiolabeled heparin can be ^(99m)Tc-heparin. Examples of otherradiolabels include, but are not limited to, ¹¹¹In, ¹⁴C, ³H, ¹³N, ¹⁸F,⁵³Cr, ¹²⁵I, ¹³³Xe, ^(81m)Kr, and ¹³¹I. Other radiolabels that can beattached to a substance, for example heparin, can be found in Table 1. Aradiolabel, for example, ^(99m)Tc, can be attached to a substance, forexample heparin, using commercially available regents well known topersons of ordinary skill in the art. In one aspect, ^(99m)Tc-heparincan be prepared as shown in Example 1 below.

TABLE 1 Commonly utilized radiolabels Nuclide Physical half-life ³H 12.3years ¹¹C 20.4 minutes ¹³N 10 minutes ¹⁴C 5730 years ¹⁵O 2 minutes ¹⁸F110 minutes ³²P 14.3 days ⁵¹Cr 27.7 days ⁵²Fe 8.3 hours ⁵⁷Co 271 days⁵⁸Co 71 days ⁵⁹Fe 45 days ⁶⁰Co 5.2 years ⁶²Zn 9.3 hours ⁶²Cu 9.7 minutes⁶⁴Cu 12.7 hours ⁶⁷Cu 2.6 days ⁶⁷Ga 78.2 hours ⁶⁸Ga 68 minutes ⁷⁶Br 16hours ^(81m)Kr — ⁸²Rb 75 seconds ⁸²Sr 25.5 days ⁸⁶Y 14.74 hours ⁸⁹Zr3.27 days ⁸⁹Sr 50.6 days ⁹⁰Sr 28.5 years ⁹⁰Y 2.7 days ⁹⁹Mo 66 hours^(99m)Tc 6.0 hours ¹¹¹In 2.8 days ¹¹³In 100 minutes ¹²³I 13.2 hours ¹²⁴I4.2 days ¹²⁵I 60 days ¹³¹I 8.0 days ¹³³Xe 5.3 days ¹³⁷Cs 30 years ¹⁵³Sm1.9 days ¹⁸⁶Re 3.8 days ²⁰¹Tl 73 hours

In one aspect, a radiolabeled contrast agent, for example^(99m)Tc-heparin, can be administered to a subject orally or byintravenous injection. Oral dosing can entail ingestion similar toroutine barium studies of the esophagus. A radiolabeled contrast agentcan be suspended in a thickened mixture (i.e., sucralose). Examples ofthickening agents include, but are not limited to, dietary starches,such as agar-agar, alginate, carrageenan, cassia gum, cellulose gum,gellan gum, guar gum, hydroxypropylcellulose, konjac gum, locust beangum, methylcellulose, hydroxypropylmethylcellulose, microcrystallinecellulose, pectin, and xanthan gum. Other viscosifiers include honey,agave nectar, date nectar, Kuzu or Kudzu root, arrow root, corn syrup,thick juices, maple syrup, coconut oil, and palm oil.

The dwell time in the esophagus can be controlled by varying theviscosity of a contrast agent and by increasing the time intervalbetween swallows, thereby providing more time for a contrast agent tocontact and bind to an eosinophil granule protein. Further, having asubject lie down with head below feet, so that there is some refluxwithin the esophagus, can prolong contact between a contrast agent andthe mucosal tissue of the esophagus in a subject.

A radiolabeled contrast agent can be administered to a subject in avolume from about 0.5 mL to about 1,000 mL, including all volumes inbetween 0.5 mL and 1,000 mL. A person of skill can determine by methodswell known in the art the volume of a contrast agent to be administeredto a subject based on the age, sex, weight, and overall condition of asubject. For example, in one aspect, the volume of a contrast agentadministered to a subject can be from about 0.5 mL to about 5 mL. Inanother aspect the volume of a contrast agent administered to a subjectcan be form about 5 mL to about 250 mL. In another aspect, the volume ofa contrast agent administered to a subject can be from about 10 mL toabout 125 mL. In another aspect, the volume of a contrast agentadministered to a subject can be from about 15 mL to about 100 mL. Thus,the volume of a contrast agent that can be administered to a subject canbe, for example, about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26,27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44,45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62,63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80,81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98,99, or 100 mL, and all volumes in between.

A person of ordinary skill in the art can administer to a subject acomposition comprising one or more radiolabeled contrast agents toenhance the detection of eosinophil granule proteins in the mucosaltissue of the esophagus in a subject. For example, such a compositioncan comprise ^(99m)Tc-heparin, ¹¹¹In-heparin, or ¹⁴C-heparin, or anycombination thereof. In one aspect, a radiolabeled contrasts agent canbe ^(99m)Tc-heparin. Examples of radiolabeled heparin/eosinophil granuleprotein complexes include, but are not limited to,^(99m)Tc-heparin/MBP-1, ^(99m)Tc-heparin/MBP, ^(99m)Tc-heparin/MBP-2,^(99m)Tc-heparin/EDN, ^(99m)Tc-heparin/ECP, and ^(99m)Tc-heparin/EPO.

After administering to a subject a composition comprising radiolabeledheparin, for example ^(99m)Tc-heparin, a person of skill can use one oremore technologies and processes to detect radiolabeledheparin/eosinophil granule protein complexes in the mucosal tissue ofthe esophagus in a subject, where eosinophils have degranulated andcaused one or more patches of inflammation, to create a medical image tomap the distribution of inflammation and deposition of eosinophilgranule proteins to study the anatomy and/or pathophysiology ofeosinophilic esophagitis. Examples of technologies that can be used tocreate a medical image include, but are not limited to, single photonemission computed tomography (SPECT), positron emission (PET) scans,X-ray, conventional or computed tomography (CT), a combination of SPECTand CT, or magnetic resonance imaging (MRI). In one aspect, for example,SPECT can optionally be used in combination with MRI and/or CT scans toproduce a medical image of an esophagus having patches of eosinophilicesophagitis. Fiduciary markers on the skin of a subject can also be usedto position a subject so that the subject can be imaged from day to day.For example, lasers can bused to position a subject reproducibly. Thispermits use of multiple scans to be precisely compared. In one aspect, amedical image can be three-dimensional. In another aspect, a medicalimage can be two-dimensional.

Also disclosed is a method of diagnosing eosinophilic esophagitis in asubject, comprising detecting an eosinophil granule protein in themucosal tissue of the esophagus in a subject, comprising administeringto a subject radiolabeled heparin under conditions wherein theradiolabeled heparin can bind to an eosinophil granule protein, anddetecting a radiolabeled heparin/eosinophil granule protein complex inthe mucosal tissue of the esophagus, whereby detecting the radiolabeledheparin/eosinophil granule protein complex in the mucosal tissue of theesophagus diagnoses; eosinophilic esophagitis in the subject. In oneaspect, a radiolabeled heparin/eosinophil granule protein complex can be^(99m)Tc-heparin/MBP-1.

In one aspect, a radiolabeled contrast agent, for example^(99m)Tc-heparin, can be administered to a subject orally. Oral dosingcan entail ingestion similar to routine barium studies of the esophagus.A radiolabeled contrast agent can be suspended in a thickened mixture(i.e., sucralose). Examples of thickening agents include, but are notlimited to, dietary starches, such as agar-agar, alginate, carrageenan,cassia gum, cellulose gum, gellan gum, guar gum, hydroxypropylcellulose,konjac gum, locust bean gum, methylcellulose, hydroxypropylmethylcellulose, microcrystalline cellulose, pectin, and xanthan gum.Other viscosifiers include honey, agave nectar, date nectar, Kuzu, Kudzuroot, arrow root, corn syrup, thick juices, maple syrup, coconut oil,and palm oi.

The dwell time in the esophagus can be controlled by varying theviscosity of a contract agent and by increasing the time intervalbetween swallows, thereby providing more time for a contras agent tocontact and bind to an eosinophil granule protein. Further, having asubject lie down with head below feet, so that there is some refluxwithin the esophagus, can prolong contact between a contrast agent andthe mucosal tissue of the esophagus in a subject.

A radiolabeled contrast agent can be administered to a subject in avolume from about 0.5 mL to about 1,000 mL, including all volumes inbetween 0.5 mL and 1,000 mL. A person of skill can determine by methodswell known in the art the volume of a contrast agent to be administeredto a subject based on the age, sex, weight, and overall condition of asubject. For example, in one aspect, the volume of a contrast agentadministered to a subject can be from about 0.5 mL to about 5 mL. Inanother aspect, the volume of a contrast agent administered to a subjectcan be from about 5 mL to about 250 mL. In another aspect, the volume ofa contrast agent administered to a subject can be from about 10 mL toabout 125 mL. In another aspect, the volume of a contrast agentadministered to a subject can be from about 15 mL to about 100 mL. Thus,the volume of a contrast agent that can be administered to a subject canbe, for example about 15, 15, 17, 18, 19, 20, 21, 22,23, 24, 25, 26,27,28, 29 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45,46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63,65, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81,82, 83, 84, 85, 86, 87, 88, 89,909, 91, 92, 93, 94, 95, 96, 97, 98, 99,or 100 mL, and all volumes in between.

A person of ordinary skill in the art can administer to a subject acomposition comprising one or more radiolabeled contrast agents toenhance the detection of eosinophil granule proteins in die mucosaltissue of the esophagus in a subject. For example, such a compositioncan comprise ^(99m)Tc-heparin, ¹¹In-heparin, or ¹⁴C-heparin, or anycombination thereof. In one aspect, a radiolabeled contrast agent can be^(99m)Tc-heparin, Examples of radiolabeled heparin/eosinophil granuleprotein complexes include, but are not limited to,^(99m)Tc-heparin/MBP-1, ^(99m)Tc-heparin/MBP, ^(99m)Tc-heparin/MBP-2,^(99m)Tc-heparin/EDN, ^(99m)Tc-heparin/ECP, and ^(99m)Tc-heparin/EPO.

After administering to a subject a composition comprising a radiolabeledheparin, for example ^(99m)Tc-heparin, a person of skill can use one ormore technologies and processes to detect radiolabeledheparin/eosinophil granule protein complexes in the mucosal tissue ofthe esophagus in a subject, where eosinophils have degranulated andcaused one or more patches of inflammation, to create a medical image tomap the distribution of inflammation and deposition of eosinophilgranule proteins to study the anatomy and/or pathophysiology ofeosinophilic esophagitis. Example of technologies that can be used tocreate a medical image include, but are not limited to, single photonemission computed tomography (SPECT), positron emission (PET) scans,X-ray, conventional or computed tomography (CT), a combination of SPECTand CT, or magnetic resonance imaging (MRI). In one aspect, for example,SPECT can optionally be used in combination with MRI and/or CT scans toproduce a medical image of an esophagus having patches of eosinophilicesophagitis. Fiduciary markers on the skin of a subject can also be usedto position a subject reproducibly. This permits use of multiple scansto be precisely compared. In one aspect, a medical image can bethree-dimensional. In another aspect, a medical image can betwo-dimensional.

Further disclosed is a method of detecting a change in eosinophilicesophagitis in a subject diagnosed with eosinophilic esophagitis,comprising; (a) producing a first medical image of the esophagus in asubject diagnosed with eosinophilic esophagitis according to thedisclosed methods, (b) producing a second medical image of the esophagusin the subject of step (a) according to the disclosed methods, and (c)comparing the medical image of step (b) with the medical image of step(a), whereby detecting a change in the medical image of step (b)compared to the medical image of step (a) detects a change in theeosinophilic esophagitis in the subject. In one aspect the medical imagecan be three-dimensional. In another aspect, the medical image can betwo-dimensional.

Thus, a person of skill can produce a first medical image of theesophagus in a subject diagnosed with EoE to have as a baseline forfuture comparison with later-produced medical images of the esophagus inthe subject to determine what the natural history of EoE is. Further, afirst medical image can be used to determine whether a treatment of EoEis effective in the subject. For example, if a second medical image isproduced after the initiation of treatment of EoE in a subject and thesecond medial image shows fewer areas of radiolabeled heparin/eosinophilgranule protein complexes (i.e., inflammation) when compared to thefirst medical image produced before initiation of treatment, a person ofskill, for example a physician, can determine that the treatment of EoEin the subject is effective. Conversely, if a second medical image isproduced after the initiation of treatment of EoE in a subject and thesecond medical image shows the same or more areas of radiolabeledheparin/eosinophil granule protein complexes (i.e., inflammation) whencompared to the first medical image produced before initiation oftreatment, a person of skill, for example a physician, can determinethat the treatment of EoE in the subject is not effective.

In another aspect, disclosed is a method of detecting eosinophildegranulation in a subject, comprising detecting an eosinophil granuleprotein in a subject, comprising administering to a subject radiolabeledheparin under conditions wherein the radiolabeled heparin can bind to aneosinophil granule protein, and detecting a radiolabeledheparin/eosinophil granule protein complex, whereby detecting theradiolabeled heparin/eosinophil granule protein complex detectseosinophil degranulation in the subject.

In one aspect, a radiolabeled contrast agent, for example ^(99m)Tc-heparin, can be administered to a subject orally or intravenously.Oral dosing can entail ingestion similar to routine barium studies ofthe esophagus. A radiolabeled contrast agent can be suspended in athickened mixture (i.e., sucralose). Examples of thickening agentsinclude, but are not limited to, dietary starches, such as agar-agar,alginate, carrageenan, cassia gum, cellulose gum, gellan gum, guar gum,hydroxypropylcellulose, konjac gum, locust bean gum, methylcellulose,hydroxypropyl methylcellulose, microcrystalline cellulose, pectin, andxanthan gum. Other viscosifiers include honey, agave nectar, datenectar, Kuzu or Kudzu root, arrow root, corn syrup, thick juices, maplesyrup, coconut oil, and palm oil.

The dwell time in the esophagus can be controlled by varying theviscosity of a contrast agent and by increasing the time intervalbetween swallows, thereby providing more time for a contrast agent tocontact and bind to an eosinophil granule protein. Further, having asubject lie down with bead below feet, so that there is some refluxwithin the esophagus, can prolong contact between a contrast agent: anddie mucosal tissue of the esophagus in a subject.

A radiolabeled contrast agent can be administered to a subject in avolume form about 0.5 mL to about 1,000 mL, including all volumes inbetween 0.5 mL and 1,000 mL. A person of skill can determine by methodswell known in the art the volume of a contrast agent to be administeredto a subject based on the age, sex, weight, and overall condition of asubject. For example, in one aspect, the volume of a contrast agentadministered to a subject can be from about 0.5 mL to about 5 mL. Inanother aspect, the volume of a contrast agent administered to a subjectcan be from about 5 mL to about 250 mL. In another aspect, the volume ofa contrast agent administered to a subject can be from about 10 mL toabout 125 mL. In another aspect, the volume of a contrast agentadministered to a subject can be from about 15 mL to about 100 mL. Thus,the volume of a contrast agent that can be administered to s subject canbe, for example, about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26,27, 28, 29 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44,45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62,63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80,81, 82, 83, 84, 85, 86, 87, 88 89, 90, 91, 92, 93, 94, 95, 96, 97, 98,99, or 100 mL, and all volumes in between.

A person of ordinary skill in the art can administer to a subject acomposition comprising one or more radiolabeled contrast agents toenhance the detection of eosinophil granule proteins in the mucosaltissue of the esophagus in a subject. For example, such a compositioncan comprise ^(99m)Tc-heparin, ¹¹In-heparin, or ¹⁴C-heparin, or anycombination thereof. In one aspect, a radiolabeled contrast agent can be^(99m)Tc-heparin. Examples of radiolabeled heparin/eosinophil granuleprotein complexes include, but are not limited to,^(99m)Tc-heparin/MBP-1, ^(99m)Tc-heparin/MBP, ^(99m)Tc-heparin/MBP-2,^(99m)Tc-heparin/EDN, ^(99m)Tc-heparin/ECP, and ^(99m)Tc-heparin/EPO.

After administering to a subject a composition comprising radiolabeledheparin, for example ^(99m)Tc-heparin, a person of skill can use one ormore technologies and processes to detect radiolabeledheparin/eosinophil granule protein complexes in the mucosal tissue ofthe esophagus in a subject, where eosinophils have degranulated andcaused one or more patches of inflammation, to create a medical image tomap the distribution of inflammation and deposition of eosinophilgranule proteins to study the anatomy and/or pathophysiology ofeosinophilic esophagitis. Examples of technologies that can be used tocreate a medical image include, but are not limited to, single photonemission computed tomography (SPECT), positron emission (PET) scans,X-ray, conventional or computed tomography (CT), combination of SPECTand CT, or magnetic resonance imaging (MRI). In one aspect, for example,SPECT can optionally be used in combination with MRI and/or CT scans toproduce a medical image of an esophagus having patches of eosinophilicesophagitis. Fiduciary markers on the skin of a subject can also be usedto position a subject so that the subject can be imaged from day today.For example, lasers can be used to position a subject reproducibly. Thispermits use of multiple scans to be precisely compared. In one aspect, amedical image can be three-dimensional. In another aspect, a medicalimage can be two-dimensional.

EXAMPLES

The following examples are put forth so as to provide those of ordinaryskill in the art with a complete disclosure and description of how thecompounds, compositions, articles, devices and/or methods claimed hereinare made and evaluated and are intended to be purely exemplary and arenot intended to limit the disclosure. Efforts have been made to ensureaccuracy with respect to numbers (e.g., amounts, temperatures, etc.),but some errors and deviations should be accounted for. Unless indicatedotherwise, parts are parts by weight; temperature in ° C. or is atambient temperature; and pressure is at or near atmospheric.

Example 1 Preparation of ^(99m)Tc-Heparin

Solutions of stannous chloride (40 mg/mL, Sigma 243523) were prepared indeionized water under flowing nitrogen. A 0.5 mL aliquot was filteredand mixed with 1.00 mL NaCl (1.00 M) plus 150 mg of preservative-freeheparin (10,000 IU/mL). Approximately 100 mCi of freshly eluted ^(99m)Tcwas added and mixed for 30 minutes at room temperature. Aliquotscontaining approximately 10 mCi of ^(99m)Tc and 20 mg of heparin wereremoved for tissue experiments. FIG. 3A shows the labeling affinity,measured by paper chromatography Whatman number 35 with acetone, showedmore than 97% binding of heparin to ^(99m)Tc. Radiolabeled heparin wasalso analyzed by Sephadex G25 column chromatography (HiTrap 5 mLdesalting columns, GE healthcare, 17140801) with 0.15 M NaCl as theelution buffer, and approximately 1 mL fractions were collected. FIG. 3Bshows radioactivity eluted at fraction 4 (free ^(99m)Tc elutes atfraction 13), demonstrating that all of the ^(99m)Tc eluted at the voidvolume and confirming that there is no unbound ^(99m)Tc in theradiolabeled heparin. The stability of ^(99m)Tc-heparin in an acidicenvironment was tested by diluting in artificial gastric juice(Carolina, 865603) and showing that is properties were unaltered, usingboth paper chromatography and Sephadex G25.

Example 2 Esophageal Biopsies

Esophageal biopsies were collected from a prior elemental diet study(IRB 00040035 University of Utah) and kept frozen at −70° C. Biopsiesfrom each patient were selected for histological analysis for eosinophildensity or radiolabeling. Biopsies from EoE patients who resolved theireosinophilia under the elemental diet were chosen as negative controls.Tissues from resolved EoE and active EoE patients were incubated withthe ^(99m)Tc-heparin, washed in buffered saline, and imaged using SPECT.

Example 3 Analysis of Radiolabeled Biopsies

The activity of radiolabeled biopsy tissues was measured using dosecalibrators (Capintec model CRC-15R). Two-dimensional planar staticimages of the radiolabeled biopsies were obtained using the Ecam SPECTinstrument (Siemens). The images were acquired for 3 minutes each usinga 1.0 magnification, 256 by 235 matrix size. Correlation betweeneosinophil densities and SPECT counts obtained by 2D imaging wereevaluated by Spearman rank correlation analysis.

Table 2 presents the SPECT counts of each biopsy, summarizing itsradioactivity and eosinophil density. Histopathological analysesconfirmed that only samples 1-5 had greater than 15 eosinophils/hpf.FIGS. 1 and 2 show that active EoE cases can be differentiated fromresolved BoE eases using this technique. The Spearman rank correlationanalysis found a monotonic correlation between eosinophil density andSPECT count with ay value less than 0.03. Even though the eosinophildensities were not derived from identical biopsy tissues used for SPECTimaging, tissues from inflamed patients displayed significant binding to^(99m)Tc-heparin that correlates with eosinophil density.

TABLE 2 Radioactivity measurements, histological data, and the SPECTcount of EoE versus control samples Sample Disease Eosinophil ActivitySPECT Number Criteria Density/hpf μCi Count 1 Active EoE 68 180 59634 2Active EoE 65 128 40474 3 Active EoE 21 101 46457 4 Active EoE 23 13159923 5 Active EoE 21 70 31780 6 Resolved EoE 10 147 47048 7 ResolvedEoE 1 29.3 13202 8 Resolved EoE 1 37 17518

Example 4 Quality Control of Radiolabeled Heparin

Thin layer chromatography (TLC) can be performed on Whatman 31ET stripswith acetone as the solvent. A chromatography chamber can be prepared byadding just enough acetone solvent so that it covers the bottom of thechromatography chamber. A small sample of ^(99m)Tc-heparin can be placedat 1 cm from the bottom of the strip. This is the origin. A spotted SGstrip can be placed into the chromatography chamber making sure that theorigin of the sample is not immersed in the solvent. When the solventreaches the top of the strip, the solvent front, the strip can beremoved front the chromatography chamber. The strip can be cut in halfbetween the origin and solvent front. Each strip can be counted usingthe Ludlum 2200 scaler/ratemeter attached to a 1″×1″ sodium iodidedetector. Each strip can be counted for 1 minute (cpm). A background(bkg) count can be obtained before counting each strip. The backgroundcount can be subtracted from each count. The radiochemical purity for^(99m)Tc-heparin can be calculated using the following formula:

Background cpm (bkg), Origin cpm, and Solvent Front cpm are measured.

${{Percentage}\mspace{14mu} {\,^{99m}{Tc}}\text{-}{heperin}} = \frac{\left( {{{Origin}\mspace{14mu} {cpm}} - {{bkg}\mspace{14mu} {cpm}}} \right)}{\left( {{{Origin}\mspace{14mu} {cpm}} - {{bkg}\mspace{14mu} {cpm}}} \right) + \left( {{{Solvent}\mspace{14mu} {Front}\mspace{14mu} {cpm}} - {{bkg}\mspace{14mu} {cpm}}} \right)}$

The final product can be clear and free of particulate matter. Theradiochemical purity for ^(99m)Tc-heparin can be >90%.

Example 5 Alternative Preparation of ^(99m)Tc-Heparin

^(99m)Tc-heparin was prepared by diluting stannous chloride (5 mg/mL,Sigma 24352) in water under flowing nitrogen. A 0.1 mL aliquot wasfiltered and mixed with 15 mg of preservative free heparin (10,000IU/mL). Approximately 5 mCi of freshly eluted ^(99m)Tc was added andmixed in for 15 minutes at room temperature. Hundred microliter aliquotscontaining approximately 0.5 mCi of ^(99m)Tc and 1.5 mg of heparin wereremoved for oral administration to mice. Quality control was determinedby paper chromatography (Whatman no. 31) with acetone.

Example 6 Quantitative Organ Biodistribution

All animal experiments were performed in accordance with approvedUniversity of Utah Institutional Animal Care and Use Committee (IACUC)protocols. ^(99m)Tc-heparin (approximately 0.5 mCi/mouse, 15 mg) wasadministered directly to the stomach of healthy adult mice (C57B1/6,Charles River Laboratories International, Inc., average weight=29.15±1.5g) by oral gavage under brief restraint using a straight 1.5 in.,20-gauge needle with a 1.25 mm ball tip. Three animals per group wereeuthanized with CO₂ at 45 minute, 1.5, 3, 6, 18, and 30 hours. With careto avoid cross-contamination, whole organs, blood and hind leg musclesamples were harvested within approximately 20 min, weighed, and countedfor up to 2 min in captus 3000 well counter (Bicom model 2MW2/2-X Naldrilled well crystal detector in a Canberra 727 well). The proximallarge intestine was considered to include the caecum plus ¾ in distalsmall intestine, while the remainder was considered distal largeintestine. Larynx and thyroid were harvested and measured together. Nogastrointestinal pelvic samples included reproductive organs andsurrounding fatty tissue. Results are expressed as the percentageinjected dose per gram of harvested organ (% ID/g).

The biodistribution of ^(99m)Tc-heparin acquired at time of harvest asmeasured by well counting is shown in FIG. 6. Forty-five minutes afteroral administration, the stomach and small intestine were the majororgan of ^(99m)Tc-heparin accumulation. The proximal large intestineshowed the highest uptake at 1.5 h after oral administration. Themajority of activity after 6 h incubation of ^(99m)Tc-heparin was indistal large intestine. Little uptake was observed in esophagus, lungand thyroid. The very modest uptake in the esophagus may be due toesophageal reflux associated with the oral gavage. All other organsshowed negligible uptake in all the time points, indicating that^(99m)Tc-heparin is not absorbed significantly outside of the GI tract.

Example 7 SPECT Imaging

To obtain qualitative images of ^(99m)Tc activity, mice wereanesthetized with isoflurane gas (5% induction, 1-2% maintenance,IMWI/VetOne, Meridian, ID, Cat#501017) and positioned prone on thescanner bed 40 min prior to euthanasia time. SPECT/CT images of micewere acquired by using an INVEON™ trimodality PET/SPECT/CT scanner(Siemens Preclincial Solutions, Knoxville, Tenn.). A sensor (Biovet,France) was used to monitor the respiration rate of mice underanesthesia. CT images consisting of 220 degrees and 480 projections ateach of 2 bed positions were acquired first. The exposure time was 135ms with a detector setting at 80 peak kilovoltage (kVp) and 500 μA. Datawere reconstructed onto a 416×416×752 image matrix using the COBRAsoftware packet (Exxim Computing Corporation, Pleasonton, Calif.). Theeffective image pixel size was 97 μm. SPECT data were acquiredimmediately following the CT using a 2 mm single pinhole collimator witha detector radius of rotation at 35 mm. Images were acquired over 1.5detector revolutions wit 6° between each of 90 projections. A 909 mm bedtravel was used. Each projection was acquired for 12 seconds, and thedata were histogrammed with a 10% window centered at 140 keV.Reconstruction was performed using ordered subset expectationmaximization 3D 9OSEM3D) with 8 iterations and 6 subsets. Reconstructedimages were analyzed and visualized using the Siemens INVEON™ ResearchWorkplace (IRW) software.

To visually track the radiolabeled dose in mice, qualitative images of^(99m)Tc activity were obtained with SPECT/CT, SPECT/CT images of micewere acquired at 3, 6, 18 and 30 hours after oral administration. FIG. 7shows the activity mostly in the GI tract, i.e., stomach and intestines.No localization was visualized in liver, kidney, or lung, indicatingthat ^(99m)Tc-heparin was not absorbed through the GI tract and was notcirculating in the blood.

Example 8 Radiation Dose Calculation for Orally Administered^(99m)Tc-heparin

The OLINDA/EXM dose estimation software was used to determine theeffective doses and doses to individual organs on calculations andconstants defined in the ICRP Publication 106. This software includes akinetic input module with exponential curve fitting of the input datafor determining the number of disintegrations per unit of administeredactivity (μCi-h/μCi) in each source organ. Residence times in thevarious organs were measured using trapezoidal averaging of the averageddata for each time interval.

Radiation dose calculations were performed based on the data obtainedfrom mice administered ^(99m)Tc-heparin by oral gavage. The data wereobtained from 18 mice sacrificed at six time intervals, with a total ofthree data points at each time interval. Dose calculations wereperformed based on the simple average of the three data points at eachtime interval. The 95% confidence interval was calculated based on thesedata points.

Good recovery of the ^(99m)Tc-heparin was observed. Between 89 and 99%of the administered material and 99% of the material measured just priorto sacrifice was recovered.

Residence times in the carious organs ere measured using trapezoidalaveraging of the averaged data for each time interval. A simple averageof the data was used.

Mouse to human estimate was performed through simple mass weightingtechniques. Human data were based on ICRP 106 values. Mouse data weremeasured for each mouse and individual organ. Simple averages ofmouse-to-human estimates were used.

Data were collected for 22 different organs. However, over 98% of theaccumulated activity was observed in the GI tract. FIG. 8 shows theaverage net activity (μCi) at each time interval. The uptake by theproximal and distal intestine gradually increased over 3 and hours,respectively, and then decreased until 30 hours. Little radioactivitylevel was observed in esophagus, lung and thyroid, and negligibleactivity was observed elsewhere.

Using the average accumulated activities (scaled for mouse-to-humanestimate), the average dose to individual organs was calculated. Table 3shows the results of the estimated dose to a human from orallyadministered ^(99m)Tc-heparin. These results listed in descending orderbased on the dose to the organ. Note that greater than 98% of the organdose is to the organs of the GI tract.

TABLE 3 Dose to individual organ from orally administered^(99m)Tc-heparin, human corrected Human corrected Fraction Organ A (μCi· hr/μCi) of Total Dist. Lg. Int. 4.355E−01 2.916E−01 Small Int.4.226E−01 2.829E−01 Prox. Lg. Int. 3.602E−01 2.411E−01 Stomach 2.541E−011.701E−01 Lung 2.012E−02 1.347E−02 Urine 3.830E−04 2.564E−04 Liver2.708E−04 1.813E−04 Esophagus 2.359E−04 1.579E−04 Larynx/Thyroid1.381E−04 9.248E−05 Bladder 9.002E−05 6.026E−05 Kidney 7.918E−055.300E−05 Heart 4.281E−05 2.866E−05 Trachea 3.724E−05 2.493E−05 Pancreas2.300E−05 1.540E−05 Spleen 1.452E−05 9.719E−06 Testicles 1.206E−068.072E−07 Thymus 6.022E−07 4.032E−07 Gall Bladder 5.582E−07 3.737E−07

Having estimated residence times and organ doses, the effective dose wasestimated. In order to estimate effective dose, OLINDA/EXM doseestimation software was used. OLINDA is au FDA approved software toolfor dose estimation and has received 501(k) approval. The estimatedresidence times were input into OLIDNA. The results for adults are shownin Table 4. Note that approximately 74% of the contribution to theeffective dose is from the organs in the GI tract. The dose contributionfrom the ovaries and bone marrow was a result of the accumulatedactivity in other organs (i.e., irradiation from accumulated activity insurrounding organs). Accumulated activity in these organs was notspecifically determined.

TABLE 4 OLINDA results for Adults using estimated residence timesFraction of mGy/MBq Total Dose LLI Wall 2.46E−03 5.12E−01 Stomach Wall1.04E−03 2.17E−01 Ovaries 8.87E−04 1.85E−01 Red Marrow 1.02E−04 2.12E−02ULI Wall 6.83E−05 1.42E−02 Urinary Bladder Wall 6.64E−05 1.38E−02 Lungs4.92E−05 1.02E−02 Small Intestine 4.68E−05 9.75E−03 Liver 2.99E−056.23E−03 Uterus 1.32E−05 2.75E−03 Pancreas 8.27E−06 1.72E−03 OsteogenicCells 7.83E−06 1.63E−03 Spleen 5.61E−06 1.17E−03 Kidneys 4.84E−061.01E−03 Breasts 4.73E−06 9.85E−04 Muscle 3.00E−06 6.25E−04 Adrenals2.70E−06 5.62E−04 Skin 1.77E−06 3.69E−04 Thyroid 5.46E−07 1.14E−04Thymus 3.60E−07 7.50E−05 Brain 5.45E−09 1.13E−06 Gallbladder Wall0.00E+00 0.00E+00 Heart Wall 0.00E+00 0.00E+00 Testes 0.00E+00 0.00E+00Effective Dose 4.81E−03 (mSv/MBq)

Example 9 Patient Administration

A patient may not eat or drink anything except water after midnight thenight before the scan. An oral dose of about 10 mCi ^(99m)Tc-heparin canbe administered to the patient.

2D planar images can be acquired over time during the swallowingprocess. Additional 2D planar body images can be taken and used todetermine the relative biodistribution of ^(99m)Tc-heparin. A 3D SPECTimage can be acquired. The patient can be re-imaged after drinkingwater.

Upon completion of the study, the patient can be removed from thescanner and encouraged to void. The patient can be instructed to drinkplenty of fluids and void frequently throughout the day to help reduceradiation exposure.

Example 10 Monkey Esophagus Tissue Experiment

Monkey esophagus biopsy samples were incubated with MBP-1 (treatedsample) overnight. Samples incubated with PBS were used as a negativecontrol. Radiolabeled binding of ^(99m)Tc-heparin was examined as afunction of washing steps with PBS, time, and heparin molarity. Resultsof binding experiments are shown in FIG. 4. FIG. 5 shows arepresentative SPECT image of monkey esophagus biopsy tissue afterincubation with ^(99m)Tc-heparin. Higher SPECT intensity of^(99m)Tc-heparin is clearly visible in the MBP-1 treated sample comparedto the control.

Example 11 Co-Localization of ^(99m)Tc-heparin Activity with EosinophilGranule Protein Infection Sites

In order to demonstrate in vivo targeting and intravenous administrationof the radiocontrast agent ^(99m)Tc-heparin, eosinophil granule proteinsMBP-1 and EPO were injected subcutaneously into healthy, anesthetizedC57BL6 mice to simulate local eosinophilia, as a positive control.^(99m)Tc-heparin was administered intravenously via tail vein after theinjection of the eosinophil granule proteins and was give time to bindthe eosinophil granule proteins. FIG. 9A depicts the sites andconcentrations of the subcutaneously injected eosinophil granuleproteins. The mice were imaged using an Inveon trimodiality scanner(Siemens Preclinical Solutions, Knoxville, Tenn.). SPECT/CT Scans werecompleted at 60 and 105 minutes after intravenous administration of^(99m)Tc-heparin.

SPECT/CT images depicting the distribution of ^(99m)Tc-heparin are shownin FIG. 9 (B-E). The ^(99m)Tc-heparin spread throughout the major bloodorgans, particularly the liver, spleen, and kidneys, as well as thebladder. However, there was additional activity at the injection sites(arrows) not present in negative control mice that had not been injectedwith eosinophil granule proteins, indicating successful co-localizationof ^(99m)Tc-heparin with the eosinophil granule proteins. Activity wasclearly visible and correlated with the concentration of MBP-1 at theinjection sites. Only the highest concentration EPO site clearly showedsignification ^(99m)Tc-heparin presence. Observations at necropsyrevealed no significant hemorrhage to confound the positive result.

REFERENCES

Abu-Ghazaleh R I, et al., “Eosinophil granule proteins in peripheralblood granulocytes,” I J Leukoc Biol 1992, 52: 611-618.

Attwood S E, et al., “Esophageal eosinophilia with dysphagia. A distinctclinicopathologic syndrome,” Dig Dis Sci 1993, 38(1): 109-116.

Esquerre J P, et al., “Kinetics of technetium-labeled heparin inthromboembolism: Preliminary Report,” Int. J. Nucl. Med. Biol., 19179: 6(4):215-220.

Fogg M I, et al., “Pollen and eosinophilic esophagitis,” J Allergy CinImmunol 2003, 112(4): 796-797.

Frigas E, et al., “Cytotoxic effects of the guinea pig eosinophil majorbasic protein on tracheal epithelium,” Lab Invest 1980, 42: 35-43.

Gangotena F, et al., “Eosinophilic Esophagitis, Ringed Esophagus: TheDiagnostic Conundrum,” Am J Gastroenterol 2007, 102: S145-S146, Abstract79.

Gleich G J et al ., “Biochemical and functional similarities betweenhuman eosinophil-derived neurotoxin and eosinophil cationic protein:homology with ribonuclease,” Proc Natl Acad Sci USA, May, 1986, 83:3145-3150.

Gleich G J et al., “Comparative properties of the Charcot-Leyden crystalprotein and the major basic protein from human eosinophils,” J ClinInvest March, 1976, 57: 633-640.

Gleich, G J et al., “Physiochemical and biological properties of themajor basic protein from guinea pig eosinophil granules,” J Exp Med1974, 140: 313-332.

Gonsalves N et al., “A Prospective Trial of Six Food Elimination Dietand Reintroduction of Causative Agents in Adults with EosinophilicEsophagitis,” Digestive Disease Week Presentation 2008, Abstract No.727.

Gonsalves N et al., “Histopathologic variability and EndoscopicCorrelates in Adults with Eosinophilic Esophagitis,” GastrointestinalEndosc 2006, 64(3):313-319.

Gonsalves N et al., “Prospective Clinical trial of Six Food EliminationDiet or Elemental Diet in the Treatment of Adults with EosinophilicGastroenteritis,” Digestive Disease Week Presentation 2009, Abstract No.S1861.

Gonsalves N, Kahrilas P., “Eosinophilic Esophagitis in Adults,” Am JGastroenterol Clin N Am 2008, 37: 349-368.

Gundel R H et al., “Human eosinophil major basic protein induces airwayconstriction and airway hyperresponsiveness in primates,” J Clin Invest,1991, 87:1470-1473.

Hiebert L M, et al., “Tissue distribution and antithrombotic activity ofunlabeled or C14-labeled porcine intestinal mucosal heparin followingadministration to rates by the oral route,” Can J Physiol Pharmacol.,2000; 78: 307-320.

Hirash J, et al., “Heparin and low-molecular-weight heparin: mechanismsof action, pharmacokinetic, dosing, monitoring, efficacy, and safety,”Chest. 2001, 119: 64S-94S.

ICRP, 2008, Radiation Dose to Patients tiaraRadiopharmaceuticals—Addendum 3 to ICRP Publication 53. ICRP Publication106. Ann. ICRP 38 (1-2).

Kagawalla A F et al., “Effect of 6 food Elimination diet on clinical andhistologic outcomes in eosinophilic esophagitis,” Clin GastroenterolHepatol 2006, 4: 1097-1102.

Kato M et al., “Eosinophil infiltration and degranulation in normalhuman tissue,” Anat Record 1998, 252:418-452.

Kephart G M et al., “Marked deposition of eosinophil-derived neurotoxinin adult patients with eosinophilic esophagitis,” Am J Gastroenterol2010, 105(2): 298-307.

Konikoff et al., “A Randomized, Double-blind, Placebo controlled trialof Fluticasone Propionate for Pediatric Eosinophilic Esophagitis,”Gastroenterol 2006, 131: 1381-1391.

Kulkami P V, et al., “Technetium Labeled Heparin: Preliminary Report ofa New Radiopharmaceutical with Potential for Imaging Damage CoronaryArteries and Myocardium,” J Nucl Med 1978, 19: 810-815.

Kulkami P V, et al., “Modified technetium-99m heparin for the imaging ofacute experimental myocardial infarcts,” J Nucl med. 1980, 21: 117-121.

Laforest M D, et al., “Pharmacokinetics and biodistribution oftechnetium 99m labelled standard heparin and low molecular weightheparin (enoxaparin) after intravenous injection in normal volunteers,”Br J Haematol. 1991, 77: 201-208.

Levine et al., “Disease of the Esophagus: Diagnosis withEsophagography,” Radiology 2005, 237: 414-427.

Liacouras C A et al., “Eosinophilic Esophagitis: a 10-year experience in381 children,” Clin Gastroenterol hepatol 2005, 3: 1198-1206.

Liacouras C, et al., “Eosinophilic Esophagitis: Updated ConsensusRecommendations for children and adults,” J Allergy Clin Immunol. 2011,128(1): 3-20.

Mackenzie S et al, “Eosinophilic Oesophagitis in Patients Presentingwith Dysphagia-A Prospective Analysis,” Aliment Pharmacol Therapeutics2008, 28(9):1140-1146.

Majdalani G, et al., “Kinetics of technetium-labeled heparin inhemodialyzed patients,” Kidney Int. Supply., 1993:41:S131-134.

Markowitz J et al., “Elemental Diet is Effective Treatment forEosinophilic Esophagitis in Children and Adolescents,” Am JGastroenterol 2003, 98: 772-782.

Mishra A et al., “An etiological role for aeroallergens and eosinophilsin experimental eosinophilic esophagitis,” J Clin Invest 2001,107:83-90.

O'Donnell M C et al., “Activation of basophil and mast cell histaminerelease by eosinophil granule major basic protein,” J Exp Med, 1983,157: 1981-1991.

Odze, R D., “Pathology of eosinophilic esophagitis: What the clinicianneeds to know,” Am J Gastroenterol 2009, 104: 485-490.

Pasha, S F, et al., “Patient characteristics, clinical endoscopic, andhistologic findings in adult eosinophilic esophagitis: a case series andsystematic review of the medical literature,” Dis Esophagus 2007, 20(4):311-319.

Pentiuk, S et al., “Dissociation between symptoms and histologicalseverity in pediatric eosinophilic esophagitis,” J Pediatr GastroenterolNutr. 2009, 48: 152-160.

Peters M S et al., “Localization of human eosinophil granule major basicprotein, eosinophil cationic protein, and eosinophil-derived neurotoxinby immunoelectron microscopy,” Lab Invest 1986, 54: 656-662.

Peterson K A, et al., “Elemental Diet Induces Histologic Response inAdult Eosinophilic Esophagitis,” Am J Gastroenterol 2013, Epub ahead ofprint.

Prasad, G A et al., “Secular trends in the epidemiology and outcomes ofeosinophilic esophagitis in Olmsted County, Minn. (1976-2007,” DigestiveDisease Week, May 2008.

Saffari H, et al., “Patchy eosinophil distributions in an esophagectomyspecimen from a patient with eosinophilic esophagitis: Implications forendoscopic biopsy,” J Allergy Clin. Immunol. 2012, 130: 798-800.

Shah, A et al., “Histophathologic variability in Children withEosinophilic Esophagitis,” Am J Gastroenterol 2009, 104(3): 716-721.

Straumann A, et al., “Natural history of primary eosinophilicesophagitis: a follow-up of 30 adult patients for up to 11.5 years,”Gastroenterology 2003, 125: 1660-1669.

Swaminathan, G J et al., “Eosinophil-granule major basic protein, AC-type lectin, binds heparin,” Biochem 2006, 44: 14152-14158.

Talley N J, Kephart G M, McGovern T W, Carpenter H A, Gleich G J.,“Deposition of eosinophil granule major basic protein in eosinophilicgastroenteritis and celiac disease,” Gastroenterology. 1992, 103:137-145.

Tantibhaedhyangkul, U et al., “Increased Esophageal Regulatory T cellsand Eosinophil Characteristics in Children with Eosinophilic Esophagitisand Gastroesophageal Reflux Disease,” Annals of Clinical & LaboratoryScience 2009, 39: 99-107.

Wagner, L et al., “Eosinophils,” Encyclopedia of Life Sciences, JohnWiley & Sons 2006.

Wang F Y et al., “Is there a seasonal variation in the incidence orintensity of allergic eosinophilic esophagitis in newly diagnosedchildren?” J Clin Gastroenterol Hepatol 2007, 41: 451-453.

Wasmoen, T L et al., “Biochemical and amino acid sequence analysis ofhuman eosinophil granule major basic protein,” J Biol Chem 1998, 263:12559-12563.

It will be apparent to those skilled in the art that variousmodifications and variations cast be made in the present inventionwithout departing torn the scope or spirit of the invention. Otheraspects of the invention will be apparent to those skilled in the artfrom consideration of the specification and practice of the inventiondisclosed herein. It is intended that the specification and examples beconsidered as exemplary only, with a true scope and spirit of theinvention being indicated by the following claims.

1.-27. (canceled)
 28. A method of producing a medical image of an organin a subject, said method comprising: administering to a subjectradiolabeled heparin wherein the radiolabeled heparin binds to one ormore eosinophil granule proteins in the tissue of the subject's organ,wherein said binding generates a radiolabeled heparin eosinophil granuleprotein complex, wherein the eosinophil granule protein is major basicprotein 1 (MBP-1), major basic protein 2 (MBP-2), eosinophil derivedneurotoxin (EDN), eosinophil cationic protein (ECP), or eosinophilperoxidase (EPO), and detecting the radiolabeled heparin eosinophilgranule protein complex in the tissue of the subject's organ, wherebydetecting the radiolabeled heparin eosinophil granule protein complex inthe tissue of the subject's organ produces a medical image of the organin the subject.
 29. The method of claim 28, wherein the radiolabel is^(99m)Tc.
 30. The method of claim 28, wherein the organ is a major bloodorgan.
 31. The method of claim 28, wherein the major blood organ is theliver, spleen, kidneys, or bladder.
 32. The method of claim 28, whereinthe organ is the esophagus, stomach, proximal large intestine, distallarge intestine, or small intestine.
 33. The method of claim 28, whereinthe organ is the heart, a lung, the skin, or the eye.
 34. The method ofclaim 28, wherein the radiolabeled heparin is administered to thesubject orally.
 35. The method of claim 34, wherein the organ is theesophagus, liver, spleen, kidneys, or bladder.
 36. The method of claim28, wherein the radiolabeled heparin is administered to the subject byintravenous injection.
 37. The method of claim 36, wherein the organ isthe esophagus, stomach, proximal large intestine, distal largeintestine, or small intestine.
 38. The method of claim 28, wherein theradiolabeled heparin is administered to the subject topically orintra-nasally.
 39. The method of claim 28, wherein the subject is ahuman.
 40. The method of claim 28, wherein the radiolabeled heparineosinophil granule protein complex is detected using one or more ofsingle-photon emission computed tomography (SPECT), positron emissiontomography (PET) scans, X-ray, conventional or computed tomography (CT),a combination of SPECT and CT, or magnetic resonance imaging (MRI). 41.A method of diagnosing an eosinophilic disease in a subject, the methodcomprising: administering to a subject radiolabeled heparin wherein theradiolabeled heparin binds to one or more eosinophil granule proteins inthe tissue of a subject's organ, wherein said binding generates aradiolabeled heparin eosinophil granule protein complex, wherein theeosinophil granule protein is major basic protein 1 (MBP-1), major basicprotein 2 (MBP-2), eosinophil derived neurotoxin (EDN), eosinophilcationic protein (ECP), or eosinophil peroxidase (EPO), and detectingthe radiolabeled heparin eosinophil granule protein complex in thetissue of the organ, whereby detecting the radiolabeled heparineosinophil granule protein complex in the mucosal tissue of the organdiagnoses an eosinophilic disease in the subject.
 42. A method ofdetecting a change in an eosinophilic disease in a subject diagnosedwith an eosinophilic disease, comprising: a) producing a first medicalimage of an organ in a subject diagnosed with an eosinophilic diseaseaccording to the method of claim 28; b) producing a second medical imageof the organ in the subject of step (a), according to the method ofclaim 28; and c) comparing the medical image of step (b) with themedical image of step (a), whereby detecting a change in the medicalimage of step (b) compared to the medical image of step (a) detects achange in the eosinophilic disease in the subject.
 43. A method ofdetecting eosinophil degranulation in a subject, the method comprising:administering to a subject radiolabeled heparin wherein the radiolabeledheparin binds to one or more eosinophil granule proteins in the tissueof a subject's organ, wherein said binding generates a radiolabeledheparin eosinophil granule protein complex, wherein the eosinophilgranule protein is major basic protein 1 (MBP-1), major basic protein 2(MBP-2), eosinophil derived neurotoxin (EDN), eosinophil cationicprotein (ECP), or eosinophil peroxidase (EPO), and detecting theradiolabeled heparin eosinophil granule protein complex in the tissue ofthe subject's organ, whereby detecting the radiolabeled heparineosinophil granule protein complex in the tissue of the organ detectseosinophil degranulation in the subject.